Focused On-demand Library for Transcription factor ATOH7

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q8N100

UPID:

ATOH7_HUMAN

Alternative names:

Atonal bHLH transcription factor 7; Class A basic helix-loop-helix protein 13; Protein atonal homolog 7

Alternative UPACC:

Q8N100

Background:

Transcription factor ATOH7, known as Atonal bHLH transcription factor 7, plays a pivotal role in the development of the retina by regulating a transcriptional program of retinal ganglion cell determinant genes. Its binding to DNA at the consensus sequence 5'-CAG[GC]TG-3' and potential dimerization with TCF3 isoform E47 underscores its significance in photoreceptor population development and retinal circadian rhythm photoentrainment.

Therapeutic significance:

The association of ATOH7 with Persistent hyperplastic primary vitreous, an autosomal recessive eye malformation, highlights its therapeutic significance. Understanding the role of ATOH7 could open doors to potential therapeutic strategies for eye diseases characterized by retinal detachment and lens opacity.